Up 9.2% in 1 day, is the Clinuvel Pharmaceuticals (ASX:CUV) share price a buy?

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is one to consider buying after jumping 9.2% higher on Thursday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price had a good day on Thursday. Shares in the Aussie pharma group rocketed 9.2% higher to lead the S&P/ASX 200 Index (ASX: XJO) winners.

So, what's causing a surge in Aussie pharma shares like Clinuvel and is it still in the buy zone?

What does Clinuvel Pharmaceuticals do?

Clinuvel is an Australian-headquartered, global pharmaceutical company. The group focuses on developing and delivering treatments for patients "with a range of severe genetic and skin disorders".

The company has operations across photomedicine, pharmaceutical and photocare within the broader industry.

As at Thursday's close, the Clinuvel share price was trading at $21.51 per share with a market capitalisation of $1.1 billion.

Why did the Clinuvel Pharmaceuticals share price surge higher?

The big announcement yesterday was an expansion of Clinuvel's SCENESSE drug (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP).

Clinuvel has made great strides in the development and application of SCENESSE for a number of years. Yesterday's announcement is the latest step as it looks to treat XP, a rare genetic disorder affecting one in one million people in the USA and Europe.

That was good news for shareholders who were quick to buy in and bid up the Clinuvel Pharmaceuticals share price.

Is the Aussie pharma share still in the buy zone?

Despite yesterday's surge, the Clinuvel Pharmaceuticals share price is down 24.9% for the year.

Given that it also trades at a price to earnings (P/E) ratio of 65.2, I'm not sure I'm keen on buying just yet.

Thursday's announcement was a promising step but I think I'd like to see more positive test results before buying.

In the meantime, I think there are some other strong candidates in the biotech and pharmaceuticals sector.

Personally, I like the look of Polynovo Ltd (ASX: PNV) as it expands into new, lucrative markets with its NovoSorb BTM technology.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »